Provided by Tiger Trade Technology Pte. Ltd.

Evommune

12.66
-0.5700-4.31%
Pre-market: 12.660.0003+0.00%05:40 EDT
Volume:571.94K
Turnover:7.27M
Market Cap:459.46M
PE:-4.85
High:13.13
Open:13.08
Low:12.61
Close:13.23
52wk High:33.20
52wk Low:10.47
Shares:36.29M
Float Shares:19.98M
Volume Ratio:1.89
T/O Rate:2.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6090
EPS(LYR):-11.2228
ROE:-52.11%
ROA:-31.99%
PB:1.66
PE(LYR):-1.13

Loading ...

U.S. Stocks on the MOVE-Williams-Sonoma, Kraft Heinz, Evommune

Reuters
·
Aug 27

Needham Starts Coverage on Evommune; Shares Gain

Reuters
·
Aug 27

Evommune Shares up 1.7% as Needham Starts Coverage

THOMSON REUTERS
·
Aug 26

Evommune Shares up 4.2% Premarket as Needham Starts Coverage with Buy Rating

THOMSON REUTERS
·
Aug 26

Needham Initiates Evommune at Buy With $28 Price Target

MT Newswires Live
·
Aug 26

Evommune, Inc. : Needham Initiates Coverage with Buy Rating; Target Price $28

THOMSON REUTERS
·
Aug 26

Evommune Price Target Announced at $28.00/Share by Needham

Dow Jones
·
Aug 26

U.S. Research Roundup- Intuit, MongoDB, Zscaler

Reuters
·
Aug 26

Analysts Are Bullish on Top NA Stocks: BitGo Holdings, Inc. Class A (BTGO), Evommune, Inc. (EVMN)

TIPRANKS
·
Aug 13

Evercore ISI Keeps Their Buy Rating on Evommune, Inc. (EVMN)

TIPRANKS
·
Aug 10

RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 07

Evommune price target lowered to $29 from $30 at RBC Capital

TIPRANKS
·
Aug 07

Analysts Conflicted on These NA Names: Fiserv (FISV), Evommune, Inc. (EVMN) and Waystar Holding Corp. (WAY)

TIPRANKS
·
Aug 07

Evommune Posts Corporate Presentation Outlining Phase 2 Inflammation-Drug Pipeline Focusing on Evo756, Evo301

Reuters
·
Aug 07

Evommune Q2 FY26 Net Loss Widens to $32.25 Million

Reuters
·
Aug 07

Evommune Starts Phase 2b Trial of Evo756 for Migraine Prevention

Reuters
·
Jul 30

Evommune - Top-Line Data from Phase 2B Trial Expected in 2027

THOMSON REUTERS
·
Jul 30

Evommune Initiates Phase 2B Clinical Trial of Mrgprx2 Inhibitor Evo756 in Migraine Prophylaxis

THOMSON REUTERS
·
Jul 30

Evommune CFO Kyle Carver Acquires 1,000 Common Shares for $13,260

Reuters
·
Jul 11

Independent Director of Evommune Arthur Kirsch Buys More Stock

Simply Wall St.
·
Jul 10